Fort Lee, NJ , Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that management will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY.
| Event | Annual ROTH Healthcare Opportunities Conference |
| Panel Title | Innovative Therapies for Solid Tumors |
| Date and Time | October 9, 2024, 12:30 pm ET |
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two clinical-stage drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator currently in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an Investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. The U.S. Food and Drug Administration granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma and ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action in that it inhibits both the catalytic and scaffolding functions of the SRC kinase thereby providing complete shutdown of the signaling pathway. NXP900 is currently in a Phase 1a dose escalation study.
Company Contact
Ron Bentsur
Chairman, Chief Executive Officer and President
201-614-3151
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Relations Contact
Christopher M. Calabrese
LifeSci Advisors
Tel: 917-680-5608
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$6.35 |
| Daily Change: | 0.29 4.79 |
| Daily Volume: | 71,948 |
| Market Cap: | US$162.600M |
November 04, 2025 September 25, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
